Nouscom
Latest round
- Series D
Last raised
- Oct 2026
Total raised
- $281M
Investors
- 27
About Nouscom
Based in Basel, Switzerland, and co-founded by Riccardo Cortese in 2015, Nouscom AG operates as a clinical-stage immuno-oncology company.8 million. Nouscom develops off-the-shelf and personalized cancer immunotherapies. The firm’s pipeline product line includes NOUS-209, which is an immunotherapy designed to treat various solid tumors and prevent cancer in individuals with Lynch syndrome; and NOUS-PEV, a personalized immunotherapy aimed at treating cancers.
Who invested in Nouscom
27 investors across 5 rounds
See all investors in Nouscom
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Nouscom
Who invested in Nouscom?
Nouscom has 27 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nouscom raised?
Nouscom has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Nouscom last raise money?
Nouscom's most recent round on record is a Series D, in Oct 2026.
What does Nouscom do?
Based in Basel, Switzerland, and co-founded by Riccardo Cortese in 2015, Nouscom AG operates as a clinical-stage immuno-oncology company.
Where is Nouscom headquartered?
Nouscom is headquartered in Basel, Switzerland.
Which VCs invest in companies like Nouscom?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Nouscom's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Nouscom? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.